278 related articles for article (PubMed ID: 21547910)
21. Fibroblast growth factor receptor (FGFR) gene amplifications are rare events in bladder cancer.
Fischbach A; Rogler A; Erber R; Stoehr R; Poulsom R; Heidenreich A; Schneevoigt BS; Hauke S; Hartmann A; Knuechel R; Veeck J; Gaisa NT
Histopathology; 2015 Apr; 66(5):639-49. PubMed ID: 24898159
[TBL] [Abstract][Full Text] [Related]
22. Fibroblast growth factor receptor-3 in urothelial tumorigenesis.
Iyer G; Milowsky MI
Urol Oncol; 2013 Apr; 31(3):303-11. PubMed ID: 22285006
[TBL] [Abstract][Full Text] [Related]
23. Frequent Telomerase Reverse Transcriptase Promoter and Fibroblast Growth Factor Receptor 3 Mutations Support the Precursor Nature of Papillary Urothelial Hyperplasia of the Urinary Bladder.
Cheng L; Lopez-Beltran A; Wang M; Whaley RD; De Souza A; Au S; Ge R; Cimadamore A; Amin A; Golijanin B; MacLennan GT; Osunkoya AO; Montironi R; Zhang S
Mod Pathol; 2023 Jul; 36(7):100151. PubMed ID: 36906071
[TBL] [Abstract][Full Text] [Related]
24. Incidence of fibroblast growth factor receptor 3 gene (FGFR3) A248C, S249C, G372C, and T375C mutations in bladder cancer.
Dodurga Y; Tataroglu C; Kesen Z; Satiroglu-Tufan NL
Genet Mol Res; 2011 Jan; 10(1):86-95. PubMed ID: 21264819
[TBL] [Abstract][Full Text] [Related]
25. Clinical significance of fibroblast growth factor receptor-3 mutations in bladder cancer: a systematic review and meta-analysis.
Liu X; Zhang W; Geng D; He J; Zhao Y; Yu L
Genet Mol Res; 2014 Feb; 13(1):1109-20. PubMed ID: 24634132
[TBL] [Abstract][Full Text] [Related]
26. Knockdown by shRNA identifies S249C mutant FGFR3 as a potential therapeutic target in bladder cancer.
Tomlinson DC; Hurst CD; Knowles MA
Oncogene; 2007 Aug; 26(40):5889-99. PubMed ID: 17384684
[TBL] [Abstract][Full Text] [Related]
27. Fibroblast growth factor receptor 3 mutation analysis on voided urine for surveillance of patients with low-grade non-muscle-invasive bladder cancer.
Zuiverloon TC; van der Aa MN; van der Kwast TH; Steyerberg EW; Lingsma HF; Bangma CH; Zwarthoff EC
Clin Cancer Res; 2010 Jun; 16(11):3011-8. PubMed ID: 20404005
[TBL] [Abstract][Full Text] [Related]
28. Prediction of progression of non-muscle-invasive bladder cancer by WHO 1973 and 2004 grading and by FGFR3 mutation status: a prospective study.
Burger M; van der Aa MN; van Oers JM; Brinkmann A; van der Kwast TH; Steyerberg EC; Stoehr R; Kirkels WJ; Denzinger S; Wild PJ; Wieland WF; Hofstaedter F; Hartmann A; Zwarthoff EC
Eur Urol; 2008 Oct; 54(4):835-43. PubMed ID: 18166262
[TBL] [Abstract][Full Text] [Related]
29. Fibroblast growth factor receptor 3 mutation in voided urine is a useful diagnostic marker and significant indicator of tumor recurrence in non-muscle invasive bladder cancer.
Miyake M; Sugano K; Sugino H; Imai K; Matsumoto E; Maeda K; Fukuzono S; Ichikawa H; Kawashima K; Hirabayashi K; Kodama T; Fujimoto H; Kakizoe T; Kanai Y; Fujimoto K; Hirao Y
Cancer Sci; 2010 Jan; 101(1):250-8. PubMed ID: 19843069
[TBL] [Abstract][Full Text] [Related]
30. Role of activating fibroblast growth factor receptor 3 mutations in the development of bladder tumors.
Zieger K; Dyrskjøt L; Wiuf C; Jensen JL; Andersen CL; Jensen KM; Ørntoft TF
Clin Cancer Res; 2005 Nov; 11(21):7709-19. PubMed ID: 16278391
[TBL] [Abstract][Full Text] [Related]
31. Chromosome 9 deletions are more frequent than FGFR3 mutations in flat urothelial hyperplasias of the bladder.
van Oers JM; Adam C; Denzinger S; Stoehr R; Bertz S; Zaak D; Stief C; Hofstaedter F; Zwarthoff EC; van der Kwast TH; Knuechel R; Hartmann A
Int J Cancer; 2006 Sep; 119(5):1212-5. PubMed ID: 16570285
[TBL] [Abstract][Full Text] [Related]
32. Fibroblast growth factor receptor 3 activation plays a causative role in urothelial cancer pathogenesis in cooperation with Pten loss in mice.
Foth M; Ahmad I; van Rhijn BW; van der Kwast T; Bergman AM; King L; Ridgway R; Leung HY; Fraser S; Sansom OJ; Iwata T
J Pathol; 2014 Jun; 233(2):148-58. PubMed ID: 24519156
[TBL] [Abstract][Full Text] [Related]
33. The role of mutations and overexpression of the fibroblast growth factor receptor-3 in bladder cancer.
Wang QY; Zhao Y; Zhang R
Minerva Med; 2015 Dec; 106(6):333-7. PubMed ID: 26542242
[TBL] [Abstract][Full Text] [Related]
34. FGFR3 and TP53 gene mutations define two distinct pathways in urothelial cell carcinoma of the bladder.
Bakkar AA; Wallerand H; Radvanyi F; Lahaye JB; Pissard S; Lecerf L; Kouyoumdjian JC; Abbou CC; Pairon JC; Jaurand MC; Thiery JP; Chopin DK; de Medina SG
Cancer Res; 2003 Dec; 63(23):8108-12. PubMed ID: 14678961
[TBL] [Abstract][Full Text] [Related]
35. The genetic difference between Western and Chinese urothelial cell carcinomas: infrequent FGFR3 mutation in Han Chinese patients.
Yuan X; Liu C; Wang K; Liu L; Liu T; Ge N; Kong F; Yang L; Björkholm M; Fan Y; Zhao S; Xu D
Oncotarget; 2016 May; 7(18):25826-35. PubMed ID: 27029078
[TBL] [Abstract][Full Text] [Related]
36. Mutations in FGFR3 and PIK3CA, singly or combined with RAS and AKT1, are associated with AKT but not with MAPK pathway activation in urothelial bladder cancer.
Juanpere N; Agell L; Lorenzo M; de Muga S; López-Vilaró L; Murillo R; Mojal S; Serrano S; Lorente JA; Lloreta J; Hernández S
Hum Pathol; 2012 Oct; 43(10):1573-82. PubMed ID: 22417847
[TBL] [Abstract][Full Text] [Related]
37. FGFR3 Mutational Activation Can Induce Luminal-like Papillary Bladder Tumor Formation and Favors a Male Sex Bias.
Shi MJ; Fontugne J; Moreno-Vega A; Meng XY; Groeneveld C; Dufour F; Kamoun A; Viborg Lindskrog S; Cabel L; Krucker C; Rapinat A; Dunois-Larde C; Lepage ML; Chapeaublanc E; Levrel O; Dixon V; Lebret T; Almeida A; De Reynies A; Rochel N; Dyrskjøt L; Allory Y; Radvanyi F; Bernard-Pierrot I
Eur Urol; 2023 Jan; 83(1):70-81. PubMed ID: 36273937
[TBL] [Abstract][Full Text] [Related]
38. TP53 codon 72 polymorphism is associated with FGFR3 and RAS mutation in non-muscle-invasive bladder cancer.
Kawahara T; Kojima T; Kandori S; Kurobe M; Yoshino T; Kimura T; Nagumo Y; Ishituka R; Mitsuzuka K; Narita S; Kobayashi T; Matsui Y; Ogawa O; Sugimoto M; Miyazaki J; Nishiyama H
PLoS One; 2019; 14(8):e0220173. PubMed ID: 31369573
[TBL] [Abstract][Full Text] [Related]
39. FGFR3 expression in primary invasive bladder cancers and matched lymph node metastases.
Turo R; Harnden P; Thygesen H; Fleischmann A; Thalmann GN; Seiler R; Cross WR; Knowles MA
J Urol; 2015 Jan; 193(1):325-30. PubMed ID: 24933362
[TBL] [Abstract][Full Text] [Related]
40. Fibroblast Growth Factor Receptor 3 Alterations and Response to PD-1/PD-L1 Blockade in Patients with Metastatic Urothelial Cancer.
Wang L; Gong Y; Saci A; Szabo PM; Martini A; Necchi A; Siefker-Radtke A; Pal S; Plimack ER; Sfakianos JP; Bhardwaj N; Horowitz A; Farkas AM; Mulholland D; Fischer BS; Oh WK; Sharma P; Zhu J; Galsky MD
Eur Urol; 2019 Nov; 76(5):599-603. PubMed ID: 31272788
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
